To Compare effects of Fingolimod and Natalizumab on preventing regional grey matter and white matter atrophy in patients with relapsing-remitting Multiple Sclerosis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

26 May 2020 Results assessing cerebellar atrophy and resting state (RS) functional connectivity (FC) in RRMS after two years of treatment, presented at the 6th Congress of the European Academy of Neurology.
12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
29 Jul 2018 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com